By Patricia Jones Ozempic lawsuits allege that Novo Nordisk failed to provide adequate warnings about serious complications associated with semaglutide, including gastroparesis, intestinal obstruction, aspiration and, in a newer group of cases, permanent vision loss.
The claims remain pending, and the allegations have not been proven at trial. Novo Nordisk disputes the lawsuits and maintains that Ozempic’s risks and benefits are appropriately communicated through its FDA-approved prescribing information.
What Is the Ozempic Lawsuit About?
Ozempic is a prescription GLP-1 receptor agonist containing semaglutide. It is FDA-approved for adults with type 2 diabetes and for reducing certain cardiovascular and kidney-related risks in qualifying patients.
Ozempic is not specifically approved as a weight-loss drug, although doctors may prescribe it off-label. Wegovy, another Novo Nordisk medication containing semaglutide, is approved for weight management in qualifying patients.
Plaintiffs generally claim that they used Ozempic as directed but later developed a severe medical condition. They allege that the manufacturer knew or should have known about the risk and failed to provide doctors and patients with a sufficiently clear warning.
These lawsuits are product-liability claims rather than criminal cases.
What Injuries Are Included in the Lawsuits?
The federal gastrointestinal litigation includes claims involving Ozempic and several other GLP-1 medicines. The official short-form complaint allows plaintiffs to identify injuries including:
- Gastroparesis
- Ileus
- Intestinal obstruction
- Ischemic bowel or ischemic colitis
- Necrotizing pancreatitis
- Gallbladder injuries
- Severe nutritional deficiencies
- Wernicke’s encephalopathy
- Pulmonary aspiration
- Death
Plaintiffs may also seek compensation for medical expenses, lost income, pain, emotional distress, disability and wrongful death when applicable.
Not every person who experiences nausea, constipation or another common side effect will have a valid lawsuit. A claimant normally needs a diagnosed injury, evidence of Ozempic use and medical support connecting the injury to the medication.
What Is Gastroparesis?
Gastroparesis is a condition in which the stomach empties much more slowly than normal even though there is no physical blockage.
Possible symptoms include:
- Persistent nausea
- Vomiting undigested food
- Abdominal pain
- Bloating
- Feeling full after eating a small amount
- Dehydration
- Difficulty maintaining proper nutrition
GLP-1 medicines slow gastric emptying as part of their mechanism. Plaintiffs argue that some patients developed severe or long-lasting gastric paralysis and were not adequately warned about that possibility.
The current Ozempic label states that its use has been associated with gastrointestinal reactions that are sometimes severe. It also says Ozempic is not recommended for patients with severe gastroparesis. The severe gastrointestinal warning was identified as a major labelling change in October 2025.
Does the Ozempic Label Mention Intestinal Obstruction?
Yes. The FDA-approved label lists ileus, intestinal obstruction and severe constipation, including fecal impaction, among adverse reactions reported after semaglutide entered the market.
However, postmarketing reports do not automatically establish that Ozempic caused a particular medical event. The FDA label explains that such reports come from a population of uncertain size, meaning their frequency and causal relationship cannot always be determined reliably.
This distinction is central to the lawsuits. Plaintiffs must prove that Ozempic was capable of causing the alleged injury and that it caused the injury in their individual case.
Pulmonary Aspiration Claims
Some lawsuits involve pulmonary aspiration during surgery or another procedure requiring general anaesthesia or deep sedation.
Aspiration can occur when stomach contents enter the lungs. Because Ozempic delays stomach emptying, food may remain in the stomach even after a patient follows normal fasting instructions.
The current label reports rare postmarketing cases of pulmonary aspiration involving GLP-1 patients who had residual stomach contents despite following preoperative fasting recommendations. It instructs patients to inform medical providers before any planned surgery or procedure.
The Federal Gastrointestinal MDL
Thousands of Ozempic and GLP-1 gastrointestinal lawsuits have been consolidated in the U.S. District Court for the Eastern District of Pennsylvania.
The proceeding is officially called:
In re Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation, MDL No. 3094
The MDL includes cases involving Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro, Zepbound and certain other GLP-1 medicines. Consolidation allows one judge to manage common pretrial matters such as document discovery, expert evidence, causation and warning-label questions.
As of July 1, 2026, the federal judiciary reported 3,848 pending cases in MDL 3094, with 3,882 cases historically included in the proceeding.
Is the Ozempic MDL a Class Action?
No. The Ozempic litigation is a multidistrict litigation, not a traditional class action.
In a class action, one or several representative plaintiffs pursue common claims for an entire group. In an MDL, each injured person normally retains an individual lawsuit.
The cases are grouped together for efficient pretrial proceedings, but each plaintiff must generally prove matters such as:
- Which medicine was used
- How long it was used
- What injury occurred
- Whether another condition may have caused the injury
- What warnings the prescribing doctor received
- The amount of the individual damages
Cases that do not settle or get dismissed may later be returned to their original federal courts for trial.
Latest Status of the Gastrointestinal Litigation
The gastrointestinal MDL remains in the pretrial expert and summary-judgment stage.
The court established deadlines for motions challenging expert testimony under Federal Rule of Evidence 702 and motions seeking summary judgment. Reply briefs supporting the summary-judgment motions were scheduled for August 7, 2026, while hearings on the expert motions were scheduled for September 10 through September 18, 2026.
These proceedings are important because the court will consider whether the plaintiffs’ experts have reliable scientific support for their causation opinions and whether certain claims may be barred or resolved before individual trials.
No court-approved global settlement amount has been established for the gastrointestinal MDL.
Ozempic Vision-Loss Lawsuits
A second and separate federal MDL now covers claims that Ozempic and certain other GLP-1 medicines caused non-arteritic anterior ischemic optic neuropathy, commonly called NAION.
NAION occurs when blood flow to the optic nerve is reduced or blocked. It can produce sudden and potentially permanent loss of vision.
Plaintiffs allege that Ozempic, Wegovy, Saxenda and Trulicity caused NAION and that manufacturers failed to provide adequate warnings. The federal judicial panel created a separate proceeding because the scientific and medical issues differ from those in the gastrointestinal litigation.
The proceeding is called:
In re GLP-1 Receptor Agonists NAION Products Liability Litigation, MDL No. 3163
As of July 1, 2026, it contained 146 pending federal cases.
Latest Status of the Vision-Loss MDL
On July 2, 2026, the court ordered early discovery and motion practice concerning two major issues:
- Whether GLP-1 medicines are capable of causing NAION
- Whether federal law or the existing warning labels affect the plaintiffs’ failure-to-warn claims
The court explained that resolving these common questions could narrow or resolve many cases. If the claims survive those early motions, the litigation may later proceed toward selecting representative bellwether cases.
The current U.S. Ozempic label contains a warning regarding diabetic-retinopathy complications and advises patients to report vision changes. However, the May 2026 label does not specifically identify NAION by name.
Who May Qualify to File an Ozempic Lawsuit?
A person may wish to seek legal advice when they:
- Used Ozempic before developing a severe diagnosed injury
- Required hospitalisation, surgery or long-term treatment
- Developed gastroparesis, intestinal obstruction, ileus, aspiration or NAION
- Experienced permanent disability or significant financial loss
- Lost a family member following a potentially related complication
- Have medical records documenting when Ozempic was prescribed and when symptoms began
Eligibility depends on the medical evidence, the law of the relevant state and the applicable filing deadline.
What Evidence May Be Needed?
Useful evidence may include:
- Pharmacy and prescription records
- Ozempic packaging or photographs of the prescription
- Medical records from before and after treatment
- Gastric-emptying studies
- Endoscopy, imaging or surgical reports
- Hospital and emergency-room records
- Ophthalmology records for vision-loss claims
- Employment and income records
- Health-insurance statements and medical bills
A person should not alter or destroy medication packaging, medical documents or communications with healthcare providers.
Is There an Ozempic Lawsuit Settlement?
There is currently no fixed settlement amount available to every Ozempic claimant. Online advertisements estimating exact payouts are speculative.
Any future compensation would likely depend on factors such as:
- The seriousness and permanence of the injury
- Whether surgery or hospitalisation was required
- The strength of the causation evidence
- Past and future medical expenses
- Lost income or reduced earning ability
- The patient’s previous medical conditions
- Whether the case involves wrongful death
The pending expert and summary-judgment decisions may significantly affect whether cases proceed toward bellwether trials or settlement negotiations.
Filing Deadlines
Every state has a statute of limitations governing product-liability and personal-injury claims. The filing period may begin on the date of injury, diagnosis or discovery of a possible connection to the medication, depending on state law.
Joining an MDL does not automatically extend every claimant’s deadline. Anyone considering a case should obtain state-specific legal advice promptly rather than waiting for an Ozempic settlement announcement.
The existence of a lawsuit does not prove that Ozempic caused an injury or that Novo Nordisk acted unlawfully. Each claim must be supported by medical and legal evidence, and patients should not stop taking a prescribed medicine without first discussing the risks with their healthcare provider.